{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:20Z","timestamp":1789578140674,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.hoc.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T15:45:05Z","timestamp":1684511105000},"page":"689-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.1016","volume":"37","author":[{"given":"Eirini","family":"Solia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2023.04.004_bib1","first-page":"56","article-title":"Waldenstr\u00f6m macroglobulinemia","volume":"13","author":"Kasi","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.004_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.004_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.004_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjh.15202","article-title":"How we manage patients with Waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Simon","year":"2018","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2023.04.004_bib5","first-page":"S112","article-title":"Waldenstr\u00f6m macroglobulinemia","volume":"17","author":"Gertz","year":"2012","journal-title":"Hematol Amst Neth"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.004_bib6","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41375-019-0592-8","article-title":"What is new in the treatment of Waldenstrom macroglobulinemia?","volume":"33","author":"Castillo","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.004_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ajh.26210","article-title":"Assessment of fixed-duration therapies for treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia","volume":"96","author":"Abeykoon","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.004_bib8","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2023.04.004_bib9","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2023.04.004_bib10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.004_bib11","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2007-09-115170","article-title":"Targeting NF-kappaB in Waldenstrom macroglobulinemia","volume":"111","author":"Leleu","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.004_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/14737140.5.3.465","article-title":"Proteasome inhibition as a therapeutic strategy for hematologic malignancies","volume":"5","author":"Mitsiades","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.004_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.004_bib14","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.004_bib15","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.004_bib16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2023.04.004_bib17","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.004_bib18","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"issue":"6765","key":"10.1016\/j.hoc.2023.04.004_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/47513","article-title":"Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta","volume":"403","author":"Nakagawa","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.004_bib20","first-page":"88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J\u00a0Immunol Baltim Md 1950"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.004_bib21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","article-title":"Bortezomib is active in patients with untreated or relapsed Waldenstrom\u2019s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.004_bib22","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom\u2019s macroglobulinemia: results of WMCTG Trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.004_bib23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2023.04.004_bib24","unstructured":"CTG Labs - NCBI. Available at: https:\/\/beta.clinicaltrials.gov\/study\/NCT00422799?tab=results. Accessed January 23, 2023."},{"issue":"6","key":"10.1016\/j.hoc.2023.04.004_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/ejh.12935","article-title":"Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstr\u04e7m macroglobulinemia","volume":"99","author":"Zhang","year":"2017","journal-title":"Eur J Haematol"},{"issue":"23","key":"10.1016\/j.hoc.2023.04.004_bib26","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.04.004_bib27","unstructured":"Treon SP. Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom\u2019s Macroglobulinemia. Published 2015. Available at: https:\/\/ash.confex.com\/ash\/2015\/webprogramscheduler\/Paper86155.html. Accessed November 6, 2022."},{"issue":"19","key":"10.1016\/j.hoc.2023.04.004_bib28","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.004_bib29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.04.004_bib30","doi-asserted-by":"crossref","unstructured":"Khwaja J, Uppal E, Baker R, et\u00a0al. Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenstr\u00f6m macroglobulinaemia including BTKi failures: A real-world analysis - Khwaja - 2022 - eJHaem - Wiley Online Library. Available at: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jha2.597. Accessed January 23, 2023.","DOI":"10.1002\/jha2.597"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.004_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.hoc.2023.04.004_bib32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood.V128.22.618.618","article-title":"R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstr\u0151m\u2019s Macroglobulinemia: A Randomised Phase II Study","volume":"128","author":"Auer","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.004_bib33","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1002\/ajh.23985","article-title":"Cyclophosphamide, bortezomib, and dexamethasone combination in Waldenstrom macroglobulinemia","volume":"90","author":"Leblebjian","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2023.04.004_bib34","doi-asserted-by":"crossref","unstructured":"Christian Buske. Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom\u2019s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial | Blood | American Society of Hematology. Published 2020. Available at: https:\/\/ashpublications.org\/blood\/article\/136\/Supplement%201\/26\/469992\/Bortezomib-in-Combination-with-Dexamethasone. Accessed November 13, 2022.","DOI":"10.1182\/blood-2020-140933"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.004_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543784.2017.1275561","article-title":"Current treatment options and investigational drugs for Waldenstrom\u2019s Macroglobulinemia","volume":"26","author":"Gavriatopoulou","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.004_bib36","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.004_bib37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.004_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.04.004_bib39","unstructured":"Meid. Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom\u2019s Macroglobulinemia | Blood | American Society of Hematology. Published 2017. Available at: https:\/\/ashpublications.org\/blood\/article\/130\/Supplement%201\/2772\/80469\/Long-Term-Follow-up-of-a-Prospective-Clinical. Accessed November 6, 2022."},{"issue":"4","key":"10.1016\/j.hoc.2023.04.004_bib40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/10428194.2018.1508668","article-title":"Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"60","author":"Chaudhry","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.hoc.2023.04.004_bib41","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstr\u00f6m Macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.hoc.2023.04.004_bib42","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.004_bib43","first-page":"2247","article-title":"Ixazomib-induced cutaneous necrotizing vasculitis","volume":"26","author":"Alloo","year":"2018","journal-title":"Support Care Cancer"},{"issue":"23","key":"10.1016\/j.hoc.2023.04.004_bib44","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A\u00a0novel orally active proteasome inhibitor ONX 0912 triggers in\u00a0vitro and in\u00a0vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.004_bib45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.hoc.2023.04.004_bib46","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-18-3728","article-title":"A\u00a0Phase Ib\/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr\u00f6m Macroglobulinemia","volume":"25","author":"Ghobrial","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.04.004_bib47","first-page":"e13","article-title":"Second-generation Proteasome Inhibition: What a Difference a Generation Makes. Clin Lymphoma Myeloma","volume":"15","author":"Boccadoro","year":"2015","journal-title":"Leuk"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.004_bib48","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1182\/blood-2007-11-120972","article-title":"Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia","volume":"111","author":"Roccaro","year":"2008","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:19:59Z","timestamp":1760185199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0889858823000382"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenstr\u00f6m Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}